Literature DB >> 25641074

Endogenous elevation of plasma cholecystokinin does not prevent gallstones.

Rafiq A Shahid1, David Q-H Wang, Brian E Fee, Shannon J McCall, Joelle M-J Romac, Steven R Vigna, Rodger A Liddle.   

Abstract

BACKGROUND: Regular gall bladder contraction reduces bile stasis and prevents gallstone formation. Intraduodenal administration of exogenous pancreatic secretory trypsin inhibitor-I (PSTI-I, also known as monitor peptide) causes cholecystokinin (CCK) secretion.
DESIGN: We proposed that stimulation of CCK release by PSTI would produce gall bladder contraction and prevent gallstones in mice fed a lithogenic diet. Therefore, we tested the effect of overexpression of rat PSTI-I in pancreatic acinar cells on plasma CCK levels and gall bladder function in a transgenic mouse line (TgN[Psti1]; known hereafter as PSTI-I tg).
RESULTS: Importantly, PSTI tg mice had elevated fasting and fed plasma CCK levels compared to wild-type (WT) mice. Only mice fed the lithogenic diet developed gallstones. Both fasting and stimulated plasma CCK levels were substantially reduced in both WT and PSTI-I tg mice on the lithogenic diet. Moreover, despite higher CCK levels PSTI-I tg animals developed more gallstones than WT animals.
CONCLUSIONS: Together with the previously observed decrease in CCK-stimulated gall bladder emptying in mice fed a lithogenic diet, our findings suggest that a lithogenic diet causes gallstone formation by impaired CCK secretion in addition to reduced gall bladder sensitivity to CCK.
© 2015 Stichting European Society for Clinical Investigation Journal Foundation.

Entities:  

Keywords:  Bile salts; cholesterol crystals; gall bladder motility; intestinal hormone; lithogenic bile; mucin gel

Mesh:

Substances:

Year:  2015        PMID: 25641074      PMCID: PMC4342269          DOI: 10.1111/eci.12400

Source DB:  PubMed          Journal:  Eur J Clin Invest        ISSN: 0014-2972            Impact factor:   4.686


  34 in total

1.  Phenotypic characterization of Lith genes that determine susceptibility to cholesterol cholelithiasis in inbred mice: physical-chemistry of gallbladder bile.

Authors:  D Q Wang; B Paigen; M C Carey
Journal:  J Lipid Res       Date:  1997-07       Impact factor: 5.922

2.  Complete mapping of crystallization pathways during cholesterol precipitation from model bile: influence of physical-chemical variables of pathophysiologic relevance and identification of a stable liquid crystalline state in cold, dilute and hydrophilic bile salt-containing systems.

Authors:  D Q Wang; M C Carey
Journal:  J Lipid Res       Date:  1996-03       Impact factor: 5.922

3.  Transgenic expression of pancreatic secretory trypsin inhibitor-I ameliorates secretagogue-induced pancreatitis in mice.

Authors:  Jaimie D Nathan; Joelle Romac; Ruth Y Peng; Michael Peyton; Raymond J Macdonald; Rodger A Liddle
Journal:  Gastroenterology       Date:  2005-03       Impact factor: 22.682

4.  Cholecystokinin bioactivity in human plasma. Molecular forms, responses to feeding, and relationship to gallbladder contraction.

Authors:  R A Liddle; I D Goldfine; M S Rosen; R A Taplitz; J A Williams
Journal:  J Clin Invest       Date:  1985-04       Impact factor: 14.808

5.  Augmented cholesterol absorption and sarcolemmal sterol enrichment slow small intestinal transit in mice, contributing to cholesterol cholelithogenesis.

Authors:  Meimin Xie; Vijay R Kotecha; Jon David P Andrade; James G Fox; Martin C Carey
Journal:  J Physiol       Date:  2012-02-13       Impact factor: 5.182

6.  Cholic acid aids absorption, biliary secretion, and phase transitions of cholesterol in murine cholelithogenesis.

Authors:  D Q Wang; F Lammert; D E Cohen; B Paigen; M C Carey
Journal:  Am J Physiol       Date:  1999-03

7.  Protection against chronic pancreatitis and pancreatic fibrosis in mice overexpressing pancreatic secretory trypsin inhibitor.

Authors:  Jaimie D Nathan; Joelle Romac; Ruth Y Peng; Michael Peyton; Don C Rockey; Rodger A Liddle
Journal:  Pancreas       Date:  2010-01       Impact factor: 3.327

8.  Effect of gallbladder hypomotility on cholesterol crystallization and growth in CCK-deficient mice.

Authors:  Helen H Wang; Piero Portincasa; Min Liu; Patrick Tso; Linda C Samuelson; David Q-H Wang
Journal:  Biochim Biophys Acta       Date:  2009-10-22

Review 9.  Regulation of cholecystokinin secretion by intraluminal releasing factors.

Authors:  R A Liddle
Journal:  Am J Physiol       Date:  1995-09

10.  Gallbladder motor function in gallstone patients: sonographic and in vitro studies on the role of gallstones, smooth muscle function and gallbladder wall inflammation.

Authors:  P Portincasa; A Di Ciaula; G Baldassarre; V Palmieri; A Gentile; A Cimmino; G Palasciano
Journal:  J Hepatol       Date:  1994-09       Impact factor: 25.083

View more
  5 in total

1.  The cholecystokinin-1 receptor antagonist devazepide increases cholesterol cholelithogenesis in mice.

Authors:  Helen H Wang; Piero Portincasa; David Q-H Wang
Journal:  Eur J Clin Invest       Date:  2016-01-12       Impact factor: 4.686

Review 2.  Obesity and Gallstones.

Authors:  Nela Melissa Parra-Landazury; Jacqueline Cordova-Gallardo; Nahum Méndez-Sánchez
Journal:  Visc Med       Date:  2021-04-23

3.  Prevention of gallbladder hypomotility via FATP2 inhibition protects from lithogenic diet-induced cholelithiasis.

Authors:  Kevin M Tharp; Amin Khalifeh-Soltani; Hyo Min Park; David A Yurek; Alaric Falcon; Louis Wong; Rouying Feng; Kamran Atabai; Andreas Stahl
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2016-03-31       Impact factor: 4.052

Review 4.  Rodent models of cholestatic liver disease: A practical guide for translational research.

Authors:  Eva Gijbels; Alanah Pieters; Kevin De Muynck; Mathieu Vinken; Lindsey Devisscher
Journal:  Liver Int       Date:  2021-02-23       Impact factor: 5.828

5.  The preference for sugar over sweetener depends on a gut sensor cell.

Authors:  Kelly L Buchanan; Laura E Rupprecht; M Maya Kaelberer; Atharva Sahasrabudhe; Marguerita E Klein; Jorge A Villalobos; Winston W Liu; Annabelle Yang; Justin Gelman; Seongjun Park; Polina Anikeeva; Diego V Bohórquez
Journal:  Nat Neurosci       Date:  2022-01-13       Impact factor: 28.771

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.